Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome

Lupus

Volumn 20, Issue 7, 2011, Pages 730-735

  Laczik, R ^a   Szodoray, P ^a,c   Veres, K ^a   Szomjak E ^a   Csipo I ^a   Sipka, S ^a   Shoenfeld, Y ^a,b   Szekanecz, Z ^a,c   Soltesz P ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b SHEBA MEDICAL CENTER   (Israel)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

acute coronary syndrome; anti oxidized LDL antibody; atherosclerosis; statin therapy

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE TEST; FEMALE; HEART ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SUDDEN DEATH;

ACUTE CORONARY SYNDROME; ADULT; AGED; AUTOANTIBODIES; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOGLOBULIN G; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 79957604404     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203311398884     Document Type: Article

References (33)

1. Libby P. Inflammation in atherosclerosis. Nature. 2002 ; 420: 868-868
2. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994 ; 90: 2126-2146 (Pubitemid 24979909)
3. Shoenfield Y, Sherer Y, Haratz D. Atherosclerosis as an infectious inflammatory and autoimmune disease. Trends Immunol. 2001 ; 22: 293-299
4. Inoue T, Uchida T, Kamishirado H, et al. Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease. J Am Coll Cardiol. 2001 ; 37: 775-779 (Pubitemid 32202444)
5. Soltesz P, Veres K, Laczik R, et al. Evaluation of antibodies to oxidized low-density lipoprotein and assessment of C-reactive protein in acute coronary syndrome and stable coronary artery disease. Thromb Haemost. 2007 ; 98: 413-419 (Pubitemid 47250245)
6. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol. 2003 ; 23: 729-736 (Pubitemid 36566160)
7. Walter DH, Dimmeler S, Zeiher AM. Effects of statins on endothelium and endothelial progenitor cell recruitment. Semin Vasc Med. 2004 ; 4: 385-393 (Pubitemid 40577827)
8. Williams JK, Sukhova GK, Herrington DM, et al. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol. 1998 ; 31: 684-691 (Pubitemid 28144138)
9. Shiomi M, Ito C. Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and lesional composition in the plaques of WHHL rabbits. Br J Pharmacol. 1999 ; 126: 961-968 (Pubitemid 29103712)
10. Bustos C, Hernandez-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition with atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol. 1998 ; 32: 2057-2064 (Pubitemid 29010476)
11. Ferro D, Parrotto S, Basili S, et al. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol. 2000 ; 36: 427-431 (Pubitemid 30624003)
12. Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Wantanabe heritable hyperlipidemic rabbits. Circulation. 2001 ; 103: 993-999 (Pubitemid 32183806)
13. Aikawa M, Rabkin E, Sugiyama S, et al. Cerivastatin, an HMG-CoA reductase inhibitor, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 2001 ; 103: 276-283 (Pubitemid 32095415)
14. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol. 1998 ; 18: 1671-1678 (Pubitemid 28521054)
15. Crisby M, Fredriksson GN, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001 ; 103: 926-933 (Pubitemid 32183796)
16. Niwa S, Totsuka T, Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol. 1996 ; 18: 669-675 (Pubitemid 27117938)
17. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001 ; 103: 357-362 (Pubitemid 32105973)
18. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med. 1996 ; 20: 707-727 (Pubitemid 26105783)
19. Steinberg D. The LDL modification hypothesis of atherogenesis: an update. J Lipid Res. 2009 ; 50 (Suppl). S376 - S381
20. Fong LG, Parthasarathy S, Witztum JL, et al. Nonenzymatic oxidative cleavage of peptide bonds in apoprotein B-100. J Lipid Res. 1987 ; 28: 1466-1477 (Pubitemid 18025879)
21. Pirillo A, Zhu W, Norata GD, et al. Oxidized lipoproteins and endothelium. Clin Chem Lab Med. 2000 ; 38: 155-160 (Pubitemid 30245784)
22. McMurray HF, Parthasarathy S, Steinberg D. Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J Clin Invest. 1993 ; 92: 1004-1008 (Pubitemid 23262425)
23. Matsuura E, Kobayashi K, Inoue K, et al. Oxidized LDL/beta2-glycoprotein I complexes: new aspects in atherosclerosis. Lupus. 2005 ; 14: 736-741 (Pubitemid 41413302)
24. Tabuchi M, Inoue K, Usui-Kataoka H, et al. The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J Lipid Res. 2007 ; 48: 768-781 (Pubitemid 46557882)
25. Freire de Carvalho J, Sherer Y, Shoenfeld Y. The fine-tuning of anti-oxidized low-density lipoprotein antibodies in cardiovascular disease and thrombosis. Thromb Haemost. 2007 ; 98: 1157-1159 (Pubitemid 350239084)
26. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 1997 ; 11: 2295-2322 (Pubitemid 27408529)
27. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res. 2005 ; 97: 1232-1235
28. Anwar KN, Fazal F, Malik AB, et al. RhoA/Rho-associated kinase pathway selectively regulates thrombin-induced intercellular adhesion molecule-1 expression in endothelial cells via activation of Iκ kinase ß and phosphorylation of RelA/p65. J Immunol. 2004 ; 173: 6965-6972 (Pubitemid 39541085)
29. Benitah SA, Valeron PF, Lacal JC. ROCK and nuclear factor-kappaB- dependent activation of cyclooxygenase-2 by Rho GTPases: effects on tumor growth and therapeutic consequences. Mol Biol Cell. 2003 ; 14: 3041-3054 (Pubitemid 36871540)
30. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998 ; 97: 1129-1135 (Pubitemid 28152885)
31. Maack C, Kartes T, Kilter H, et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation. 2003 ; 108: 1567-1574 (Pubitemid 37187782)
32. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med. 2000 ; 6: 1399-1402 (Pubitemid 32001026)
33. Nobes C, Marsh M. Dendritic cells: new roles for Cdc42 and Rac in antigen uptake?. Curr Biol. 2000 ; 10: R739 - R741